Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP diet and health study cohort

Cancer Prevention Research

Volumn 4, Issue 12, 2011, Pages 2027-2034

  Daugherty, Sarah E ^a   Moore, Steven C ^a   Pfeiffer, Ruth M ^a   Inskip, Peter D ^a   Park, Yikyung ^a   Hollenbeck, Albert ^b   Rajaraman, Preetha ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AARP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; DIET; DRUG USE; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SELF REPORT; SEX DIFFERENCE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN NEOPLASMS; DIET; FEMALE; GLIOMA; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 83055195228     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0274     Document Type: Article

References (31)

1. Central BrainTumor Registry of the United States (CBTRUS). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2010.
2. Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M. Case-control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol 2004;159:1131-9. (Pubitemid 38747260)
3. Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev 2008;17:1277-81.
4. Deininger MH, Schluesener HJ. Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma. J Neuroimmunol 1999;95:202-8. (Pubitemid 29173039)
5. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000;60:4926-31.
6. Buccoliero AM, Caldarella A, Gheri CF, Taddei A, Paglierani M, Pepi M, et al. Inducible cyclooxygenase (COX-2) in glioblastoma-clinical and immunohistochemical (COX-2-VEGF) correlations. Clin Neuropathol 2006;25:59-66.
7. Perdiki M, Korkolopoulou P, Thymara I, Agrogiannis G, Piperi C, Boviatsis E, et al. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem 2007;295:75-83. (Pubitemid 46157989)
8. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001;61:4375-81. (Pubitemid 32685762)
9. Ishibashi M, Bottone FG Jr, Taniura S, Kamitani H, Watanabe T, Eling TE. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells. Exp Cell Res 2005;302:244-52. (Pubitemid 39550466)
10. ChuangHC, Kardosh A, Gaffney KJ, Petasis NA, Schonthal AH.COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 2008;7:38.
11. Wakimoto N, Wolf I, Yin D, O'Kelly J, Akagi T, Abramovitz L, et al. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 2008;68:6978-86.
12. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
13. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55. (Pubitemid 41002838)
14. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-27. (Pubitemid 23097110)
15. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004;24:3177-84. (Pubitemid 39390970)
16. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003;88:1687-92. (Pubitemid 36760410)
17. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003;88:684-8. (Pubitemid 36411444)
18. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58. (Pubitemid 40069695)
19. Andrews J, Djakiew D, Krygier S, Andrews P. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 2002;50:277-84.
20. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR, et al. Design and serendipity in establishing a large cohort with wide dietary intake distributions: the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 2001;154:1119-25. (Pubitemid 33140635)
21. Michaud DS, Midthune D, Hermansen S, Leitzmann M, Harlan LC, Kipnis V, et al. Comparison of cancer registry case ascertainment with SEER estimates and self-reporting in a subset of the NIH-AARP Diet and Health Study. J Regist Manag 2005;32:70-75.
22. Olsen JH, Boice JD Jr, Jensen JP, Fraumeni JF Jr. Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 1989;81:803-8. (Pubitemid 19137445)
23. Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 1999;82:155-60. (Pubitemid 29293770)
24. Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Malmer B, Lonn S, et al. Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Biomarkers Prev 2005;14:643-50. (Pubitemid 40489209)
25. McCarthy BJ, Rankin K, Il'yasova D, Erdal S, Vick N, Ali-Osman F, et al. Assessment of type of allergy and antihistamine use in the development of glioma. Cancer Epidemiol Biomarkers Prev 2011;20:370-78.
26. Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007;99:1544-50. (Pubitemid 351767237)
27. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer 2002;98:609-15. (Pubitemid 34208564)
28. Schoemaker MJ, Swerdlow AJ, Hepworth SJ, McKinney PA, van TM, Muir KR. History of allergies and risk of glioma in adults. Int J Cancer 2006;119:2165-72. (Pubitemid 44423676)
29. Wigertz A, Lonn S, Schwartzbaum J, Hall P, Auvinen A, Christensen HC, et al. Allergic conditions and brain tumor risk. Am J Epidemiol 2007;166:941-50. (Pubitemid 47511691)
30. West SL, Savitz DA, Koch G, Sheff KL, Strom BL, Guess HA, et al. Demographics, health behaviors, and past drug use as predictors of recall accuracy for previous prescription medication use. J Clin Epidemiol 1997;50:975-80. (Pubitemid 27423529)
31. Pit SW, Byles JE, Cockburn J. Accuracy of telephone self-report of drug use in older people and agreement with pharmaceutical claims data. Drugs Aging 2008;25:71-80.